Company Overview and News
Jericho Oil Corp. (JCO:TSX.V; JROOF:OTC), a 26.5% owner in the Oklahoma STACK joint venture (JV), continues delineating and derisking its acreage in the Meramec and Osage Formations. "Each well drilled has the potential to generate significant returns for our company, and with over 150 gross un-risked drillable locations, there is significant net asset value within our STACK position," CEO Brian Williamson stated in a news release.
AMR JROOF JCO XTO
TULSA, Okla. and VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V: JCO; OTC PINK: JROOF) announces that its Oklahoma STACK Joint Venture (“STACK JV”) has elected to participate in its second Meramec formation well, the Valkyrie 6-19N-12W #1H, within its Blaine County STACK acreage position. In addition to the Valkyrie, the STACK JV has also elected to participate in two additional Osage formation wells to be drilled by Exxon Mobil’s subsidiary XTO Energy and Alta Mesa Resources in Major County.
CKRGZ XOM CHKVP SDRPQ JROOF CHKDH CHKVZ XTO SD CHKDG CHKWZ SDOCQ CHKDJ CHKDP CHK.WI CHK AMR JCO SDRXP SDRXQ
VANCOUVER, British Columbia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (TSX-V:JCO) (OTC PINK:JROOF) ("Jericho" or the "Company") announces that the lender under its Senior Secured Revolving Credit Facility (the “Facility”) has amended and extended the maturity date of the Facility to July 29, 2020. In addition, the borrowing base was reaffirmed at USD$7,500,000. The borrowing base is subject to semi-annual re-determinations, with the next occurring in October 2018.
TULSA, Okla. and VANCOUVER, British Columbia, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V: JCO; OTC PINK: JROOF) announces that its Oklahoma STACK Joint Venture (“STACK JV”) will commence this week with the drilling of its second Osage formation well, the Trebuchet 21-23N-10W #1H, within its northern STACK acreage position further delineating the nearly 16,000 net STACK acres.
AMR JROOF JCO
2018-08-02 oilvoice - 10
The STACK oil and gas play in Oklahoma has caught the attention of the world's largest energy company, among many other large-cap producers, but investors can also find opportunity with a small-cap active in the area.
GST-A XOM CHKVP GST-B DVN GST JROOF CHKDH CHKVZ XTO CHKDG CHKDJ CHKDP AMR JCO CKRGZ CTLR NFX CHKWZ CHK.WI CHK MRO CLR
TULSA, Okla. and VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) announces that its Oklahoma STACK Joint Venture (“STACK JV”) has brought online a successful test well of the Osage formation within its northern STACK acreage position. After more than six months of extensive geological and geophysical work, along with methodical acreage accumulation, and a strategic Osage formation test well, the Company is excited to further delineate and develop the STACK JV’s nearly 16,000 net acre position in the northern STACK.
XOM JROOF JCO XTO
2018-07-09 oilvoice - 3
Rick Rule, CEO of Sprott U.S. Holdings, speaks with Maurice Jackson of Proven and Probable about investing in precious and base metals, energy, agriculture and water.
MRZLF AMZ RIO RIO NSRPF IVN JROOF RVSDF EMX RTPPF UEC MOLOF RTNTF MAI JCO NEVDF AXDDF WPM MLRKF SPOXF RRI FCUUF MRO NVO IVPAF ATUSF RIO NCU PPT.U MRZ VGMTD FCU
Jericho Oil Corp. (JCO:TSX.V; JROOF:OTC) just made available on its website the first in a series of analyses on the North STACK oil and gas play in Oklahoma's Anadarko Super Basin.
TULSA, Okla. and VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) is pleased to report the results of its Annual General Meeting of Shareholders (the “AGM”) held on June 27, 2018.
TULSA, Okla. and VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) is releasing the first part in a planned series of analytical reviews of the North STACK by Shane Matson and Ron Haveman, lead Geologists for Jericho. Oklahoma’s STACK Play in the Anadarko Super Basin, is a massive oil and gas play due to its lateral expanse and vertical extent being centered on the Sooner Trend Giant Oil Field, the “STACK” (Sooner Trend Oil Field Anadarko Basin Canadian and Kingfisher Counties).
LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / Jericho Oil Corporation (TSX-V: JCO; OTC PINK: JROOF), a growth E&P company focused on domestic, liquids-rich unconventional resource plays, located primarily in the Anadarko basin STACK play of Oklahoma, today announced that it will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 2 PM PST / 5 PM EST. Brian Williamson, CEO, will be giving the presentation and meeting with investors.
TULSA, Okla. and VANCOUVER, British Columbia, May 11, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) announces that it has published its Annual Letter to Shareholders from CEO, Brian Williamson, on the Company's website at https://jerichooil.com/uploads/2018/05/2017-annual-letter-to-shareholders_final-002.pdf.
* JERICHO OIL CORP - DUE TO AN EXTENDED MEDICAL LEAVE OF CO’S CFO, ROBIN PETERSON, CO HAS APPOINTED BENJAMIN HOLMAN AS INTERIM CFO Source text for Eikon: Further company coverage:
TULSA, Okla. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) announces that it has retained Toronto based Trapeze Capital Corp. to provide market-making services in accordance with TSX Venture policies.
WPXP WMB JROOF JCO WPX
(Reuters) - (This version of the March 19 story corrects paragraph 1 to delete reference to shale given lead refers to Meramec, corrects paragraph 15 to show that regulators have connected use of waste water disposal wells to earthquakes instead of drilling in general)
DVN MRO JROOF JCO
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET